MAINZ BIOMED N.V. 8-K

What Happened

• Mainz Biomed N.V. (MYNZ) reported that under an equity distribution agreement with Maxim Group LLC, it sold 1,735,194 ordinary shares between January 5, 2026 and January 23, 2026.
• The sales were made under a Prospectus Supplement dated December 29, 2025 to the company’s effective Form F-3 shelf registration and generated aggregate gross proceeds of $2,152,822.40 (before commissions and expenses).

Key Details

• Sales Agreement with Maxim Group LLC originally entered October 1, 2025 (filed as Sales Agreement).
• Prospectus Supplement (Dec 29, 2025) authorized up to $2,152,823 of sales under that supplement; the company fully utilized this Prospectus Supplement.
• Aggregate shares sold: 1,735,194 ordinary shares; gross proceeds: $2,152,822.40 (commissions/fees not yet deducted).
• Overall ATM facility remains available up to $10,000,000 (aggregate ceiling under the Sales Agreement), subject to market conditions.

Why It Matters

• The company raised immediate cash (gross $2.15M) through a market-driven equity program, which can help fund operations or corporate needs without a negotiated private placement.
• These sales dilute existing shareholders modestly because new shares were issued into the market; investors should consider dilution and the net proceeds after fees.
• Although this Prospectus Supplement is fully used, Mainz still has remaining capacity under its overall $10M ATM program for future issuances if market conditions permit.